United Kingdom· GB-APID-33979811000001107
Cinqaero 100mg/10ml concentrate for solution for infusion vials
A reslizumab product containing reslizumab, registered in United Kingdom by Teva UK Ltd. The same ATC class is registered in 11 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Reslizumab is registered in 11 of 19 countries.
Countries holding a registration under ATC R03DX08 (reslizumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 7 of them publish a price we can compare per daily dose
Reslizumab · ATC R03DX08
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Reslizumab
- Manufacturer
- Teva UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- R03DX08
- ATC class
- Reslizumab
- Defined daily dose
- 7.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin5017007020455
- gtin5017007604501
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Reslizumab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCINQAEROTeva B.V., Haarlem
- SwitzerlandCinqaero 100 mg/10 mL, Konzentrat zur Herstellung einer InfusionslösungTeva Pharma AG
- FinlandCINQAEROOrifarm Oy
- BelgiumCinqaero 10 mg/mlTeva
- IrelandCINQAERO 10 mg/mL concentrate for solution for infusionTeva B.V.
- IcelandCinqaeroTeva B.V.*
- NetherlandsCinqaero 10 mg/ml concentraat voor oplossing voor infusieTeva B.V.
- PolandCinqaeroTeva B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Cinqaero
- Liechtenstein · Cinqaero
- Norway · Cinqaero
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/22e4250c-73a9-4b96-abff-52503d875d64 GET /v1/drugs/22e4250c-73a9-4b96-abff-52503d875d64?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "33979811000001107",
"desc": "Cinqaero 100mg/10ml concentrate for solution for infusion vials (Teva UK Ltd)",
"form": "Solution for infusion",
"vpid": "33999611000001101",
"source": "dmd",
"vtm_id": "781215009",
"strength": "10 mg",
"substance": "Reslizumab",
"ingredient": "Reslizumab",
"supplier_code": "3849901000001105"
}See everything about reslizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.